Atyr PHARMA (NASDAQ:ATYR) Earns Overweight Rating from Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a report issued on Friday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $17.00 price objective on the stock.

A number of other research analysts also recently commented on ATYR. Royal Bank of Canada restated an outperform rating and set a $16.00 price objective on shares of Atyr PHARMA in a research note on Wednesday, August 14th. HC Wainwright restated a buy rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Thursday, August 15th. Finally, Jefferies Financial Group began coverage on Atyr PHARMA in a research note on Thursday, September 5th. They set a buy rating and a $9.00 price objective for the company.

Atyr PHARMA Trading Up 7.5 %

Shares of NASDAQ ATYR opened at $1.87 on Friday. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50. The company has a quick ratio of 7.63, a current ratio of 7.63 and a debt-to-equity ratio of 0.01. The company has a market cap of $129.05 million, a P/E ratio of -2.08 and a beta of 1.21. The firm has a 50 day moving average price of $1.85.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. As a group, equities analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current year.

Insiders Place Their Bets

In other Atyr PHARMA news, Director Paul Schimmel purchased 41,052 shares of Atyr PHARMA stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $1.74 per share, for a total transaction of $71,430.48. Following the transaction, the director now owns 354,075 shares of the company’s stock, valued at $616,090.50. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.70% of the stock is currently owned by insiders.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.